Literature DB >> 26178862

Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin.

Femke-Anouska Heinsen1, Henrik Knecht, Sven C Neulinger, Ruth A Schmitz, Carolin Knecht, Tanja Kühbacher, Philip C Rosenstiel, Stefan Schreiber, Anette K Friedrichs, Stephan J Ott.   

Abstract

Gut microbiota play a key role in the host's health system. Broad antibiotic therapy is known to disrupt the microbial balance affecting pathogenic as well as host-associated microbes. The aim of the present study was to investigate the influence of antibiotic paromomycin on the luminal and mucosa-associated microbiota at the DNA (abundance) and RNA (potential activity) level as well as to identify possible differences. The influence of antibiotic treatment on intestinal microbiota was investigated in 5 healthy individuals (age range: 20-22 years). All participants received the antibiotic paromomycin for 3 d. Fecal samples as well as sigmoidal biopsies were collected before and immediately after cessation of antibiotic treatment as well as after a recovery phase of 42 d. Compartment- and treatment status-specific indicator operational taxonomic units (OTUs) as well as abundance- and activity-specific patterns were identified by 16S rRNA and 16S rRNA gene amplicon libraries and high-throughput pyrosequencing. Microbial composition of lumen and mucosa were significantly different at the DNA compared to the RNA level. Antibiotic treatment resulted in changes of the microbiota, affecting the luminal and mucosal bacteria in a similar way. Several OTUs were identified as compartment- and/or treatment status-specific. Abundance and activity patterns of some indicator OTUs differed considerably. The study shows fundamental changes in composition of gut microbiota under antibiotic therapy at both the potential activity and the abundance level at different treatment status. It may help to understand the complex processes of gut microbiota changes involved in resilience mechanisms and on development of antibiotic-associated clinical diseases.

Entities:  

Keywords:  16S rRNA gene; antibiotics; lumen; microbiota; mucosa

Mesh:

Substances:

Year:  2015        PMID: 26178862      PMCID: PMC4615565          DOI: 10.1080/19490976.2015.1062959

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  53 in total

Review 1.  Commensal host-bacterial relationships in the gut.

Authors:  L V Hooper; J I Gordon
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

2.  Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota.

Authors:  Vincent B Young; Thomas M Schmidt
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  In vitro alterations of intestinal bacterial microbiota in fecal samples during storage.

Authors:  Stephan J Ott; Meike Musfeldt; Kenneth N Timmis; Jochen Hampe; Dirk F Wenderoth; Stefan Schreiber
Journal:  Diagn Microbiol Infect Dis       Date:  2004-12       Impact factor: 2.803

4.  The kinemage: a tool for scientific communication.

Authors:  D C Richardson; J S Richardson
Journal:  Protein Sci       Date:  1992-01       Impact factor: 6.725

5.  Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity.

Authors:  M Kitahara; F Takamine; T Imamura; Y Benno
Journal:  Int J Syst Evol Microbiol       Date:  2001-01       Impact factor: 2.747

6.  Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces.

Authors:  J E Wells; P B Hylemon
Journal:  Appl Environ Microbiol       Date:  2000-03       Impact factor: 4.792

Review 7.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

8.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.

Authors:  S J Ott; M Musfeldt; D F Wenderoth; J Hampe; O Brant; U R Fölsch; K N Timmis; S Schreiber
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Antibiotic use and the development of Crohn's disease.

Authors:  T Card; R F A Logan; L C Rodrigues; J G Wheeler
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

10.  Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces.

Authors:  Erwin G Zoetendal; Atte von Wright; Terttu Vilpponen-Salmela; Kaouther Ben-Amor; Antoon D L Akkermans; Willem M de Vos
Journal:  Appl Environ Microbiol       Date:  2002-07       Impact factor: 4.792

View more
  20 in total

Review 1.  The resilience of the intestinal microbiota influences health and disease.

Authors:  Felix Sommer; Jacqueline Moltzau Anderson; Richa Bharti; Jeroen Raes; Philip Rosenstiel
Journal:  Nat Rev Microbiol       Date:  2017-06-19       Impact factor: 60.633

Review 2.  Association of the gut microbiome with cancer immunotherapy.

Authors:  Motoo Nomura
Journal:  Int J Clin Oncol       Date:  2022-05-14       Impact factor: 3.402

3.  Differential Responses of Digesta- and Mucosa-Associated Jejunal Microbiota of Hu Sheep to Pelleted and Non-Pelleted High-Grain Diets.

Authors:  Zhiqiang Zhong; Yuning Zhang; Xiaotong Li; Lingyun Li; Ruiyang Zhang; Shuyi Zhang
Journal:  Animals (Basel)       Date:  2022-06-30       Impact factor: 3.231

Review 4.  Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.

Authors:  Adam Shute; Dominique G Bihan; Ian A Lewis; Yasmin Nasser
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

5.  Body Mass Index and Sex Affect Diverse Microbial Niches within the Gut.

Authors:  Francesca Borgo; Stefania Garbossa; Alessandra Riva; Marco Severgnini; Carmelo Luigiano; Albero Benetti; Antonio E Pontiroli; Giulia Morace; Elisa Borghi
Journal:  Front Microbiol       Date:  2018-02-14       Impact factor: 5.640

6.  The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients.

Authors:  Aina E Fossum Moen; Jonas Christoffer Lindstrøm; Tone Møller Tannæs; Simen Vatn; Petr Ricanek; Morten H Vatn; Jørgen Jahnsen
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.996

Review 7.  Optimum health and inhibition of cancer progression by microbiome and resveratrol.

Authors:  James Stokes Iii; Sankalp Vinayak; Jazalyn Williams; Shalie Malik; Rajesh Singh; Upender Manne; Taofeek K Owonikoko; Manoj K Mishra
Journal:  Front Biosci (Landmark Ed)       Date:  2021-01-01

8.  Metagenomic Analysis of Antibiotic-Induced Changes in Gut Microbiota in a Pregnant Rat Model.

Authors:  Imran Khan; Esam I Azhar; Aymn T Abbas; Taha Kumosani; Elie K Barbour; Didier Raoult; Muhammad Yasir
Journal:  Front Pharmacol       Date:  2016-04-28       Impact factor: 5.810

9.  Spatial Heterogeneity and Co-occurrence of Mucosal and Luminal Microbiome across Swine Intestinal Tract.

Authors:  Li Zhang; Weida Wu; Yuan-Kun Lee; Jingjing Xie; Hongfu Zhang
Journal:  Front Microbiol       Date:  2018-01-26       Impact factor: 5.640

Review 10.  Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention?

Authors:  Emilie Viennois; Andrew T Gewirtz; Benoit Chassaing
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.